DNLI Q4 2018 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$126M

Gross Profit

$126M100.0% margin

Operating Income

$75M59.5% margin

Net Income

$78M61.7% margin

EPS (Diluted)

$0.79

QoQ Revenue Growth

+10416.8%

Cash Flow

Operating Cash Flow

$93M

Free Cash Flow

$92M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$662M

Total Liabilities

$115M

Stockholders' Equity

$547M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$126M	$0	—
Gross Profit	$126M	$0	—
Operating Income	$75M	-$24M	+417.4%
Net Income	$78M	-$23M	+438.8%